VRTX•benzinga•
Vertex Announces Program Updates For Type 1 Diabetes Portfolio; VX-264 Phase 1/2 Enrollment And Dosing Complete In Parts A And B: VX-264 Was Generally Safe And Well Tolerated; Efficacy Data Are Not Supportive Of Further Clinical Advancement
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 28, 2025 by benzinga